Longevity of Sm-p80-specific antibody responses following vaccination with Sm-p80 vaccine in mice and baboons and transplacental transfer of Sm-p80-specific antibodies in a baboon.
Longevity of Sm-p80-specific antibody responses following vaccination with Sm-p80 vaccine in mice and baboons and transplacental transfer of Sm-p80-specific antibodies in a baboon.
复制标题
在小鼠和狒狒中接种 Sm-p80 疫苗以及在狒狒中进行 Sm-p80 特异性抗体经胎盘转移后，Sm-p80 特异性抗体反应的寿命。
DOI：
10.1007/s00436-014-3879-8
复制
发表时间：
2014
影响因子：
2
通讯作者：
Siddiqui,AfzalA
中科院分区：
文献类型：
--
作者：
Zhang,Weidong;Ahmad,Gul;Le,Loc;Rojo,JuanU;Karmakar,Souvik;Tillery,KoryA;Torben,Workineh;Damian,RaymondT;Wolf,RomanF;White,GaryL;Carey,DavidW;Carter,Darrick;Reed,StevenG;Siddiqui,AfzalA
根据在小鼠、仓鼠和狒狒中使用疫苗效力研究获得的数据，Sm-p80作为血吸虫病第一级候选疫苗的资格已经得到充分确立。基于Sm-p80的疫苗制剂在降低尾蚴攻击后的成虫负荷方面一直表现出有效的预防功效，并诱导杀死慢性感染中已建立的蠕虫。这种疫苗对肠道和泌尿系统血吸虫病都有保护作用。在这项研究中，Sm-p80特异性抗体应答的寿命在小鼠和狒狒中进行了研究。在用Sm-p80重组疫苗（Sm-p80 + GLA-SE）接种后长达60周的小鼠中检测到稳健的抗体滴度。在我们发表的研究的后续实验中，在首次接种Sm-p80 DNA疫苗后5-8年的狒狒中也检测到Sm-p80特异性IgG。在一只狒狒中，在脐带血和婴儿中检测到Sm-p80特异性抗体的转移。这些持久的体液免疫应答数据，加上啮齿动物和非人灵长类动物中的疫苗有效性数据，进一步加强了Sm-p80通过开发进入人体临床试验的可能性。
Based on data obtained using vaccine efficacy studies in mice, hamsters, and baboons, the credentials of Sm-p80 as a first tier vaccine candidate for schistosomiasis have been well established. Sm-p80-based vaccine formulation(s) have consistently exhibited potent prophylactic efficacy in reducing adult worm burden following cercarial challenge and induce killing of established adult worms in chronic infection. This vaccine is protective against both intestinal and urinary schistosomiasis. In this study, the longevity of Sm-p80-specific antibody responses was studied in mice and in baboons. Robust antibody titers were detected in mice for up to 60 weeks following vaccination with Sm-p80 recombinant vaccine (Sm-p80 + GLA-SE). In the follow-up experiments to our published studies, Sm-p80-specific IgG was also detected in baboons 5–8 years following the initial vaccination with an Sm-p80 DNA vaccine. In one baboon, transfer of Sm-p80-specific antibody was detected in umbilical cord blood and in the baby. These long-lasting humoral immune response data coupled with the vaccine efficacy data in rodents and nonhuman primates further strengthens the case for Sm-p80 to be moved forward through development leading to human clinical trials.